CRISPR Therapeutics (NASDAQ:CRSP) Given “Neutral” Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report released on Wednesday morning,Benzinga reports. Cantor Fitzgerald also issued estimates for CRISPR Therapeutics’ FY2025 earnings at ($6.91) EPS.

A number of other equities research analysts have also recently issued reports on the stock. Bank of America reduced their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a research report on Wednesday, February 12th. JMP Securities reissued a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Chardan Capital reduced their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Finally, Citigroup reduced their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research report on Tuesday. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $74.40.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $47.91 on Wednesday. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10. The company has a market cap of $4.11 billion, a P/E ratio of -10.96 and a beta of 1.67. The firm’s fifty day moving average price is $42.25 and its two-hundred day moving average price is $46.06.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts expect that CRISPR Therapeutics will post -5.03 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CRSP. Highline Wealth Partners LLC acquired a new position in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $39,000. Western Pacific Wealth Management LP increased its stake in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $40,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $43,000. Finally, Eastern Bank acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $70,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.